Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 20/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 10/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3972746 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3974156 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3975345 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3975368 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL3961159 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL3980403 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL3973936 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL3978357 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL3975894 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3974026 | 0.99 | SLC6A2 (0.98) | SLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531543-B2 | Phenylpiperazine cycloalkanol derivatives and methods of their use | WYETH (US) | 2009-05-12 | — | — | US | claimed |
| EP-1846105-A2 | USE OF ADRENERGIC ALPHA2B ANTAGONISTS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | Wyeth (US) | 2007-10-24 | — | — | EP | claimed |
| EP-1551413-A1 | USE OF NOREPINEPHRINE REUPTAKE MODULATORS FOR PREVENTING AND TREATING VASOMOTOR SYMPTOMS | Wyeth a Corporation of the State of Delaware (US) | 2005-07-13 | — | — | EP | claimed |
| EP-1551380-A1 | A METHOD OF TREATING VASOMOTOR SYMPTOMS COMPRISING A COMPOUND HAVING NOREPINEPHRINE REUPTAKE INHIBITOR ACTIVITY AND 5-HT2A ANTAGONISTIC ACTIVITY | Wyeth (US) | 2005-07-13 | — | — | EP | claimed |
| US-20050143394-A1 | Phenylpiperazine cycloalkanol derivatives and methods of their use | WYETH (US) | 2005-06-30 | — | — | US | claimed |
| US-20050130987-A1 | Methods of treating vasomotor symptoms | WYETH (US) | 2005-06-16 | — | — | US | claimed |
| WO-2005037260-A2 | USE OF ADRENERGIC ALPHAZE ANTAGONISTS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | WYETH (US) | 2005-04-28 | — | — | WO | claimed |
| US-20040152710-A1 | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms | WYETH | 2004-08-05 | — | — | US | claimed |
| WO-2004035036-A1 | A METHOD OF TREATING VASOMOTOR SYMPTOMS COMPRISING A COMPOUND HAVING NOREPINEPHRINE REUPTAKE INHIBITOR ACTIVITY AND 5-HT2A ANTAGONISTIC ACTIVITY | WYETH (US) | 2004-04-29 | — | — | WO | claimed |
| WO-2004035058-A1 | USE OF NOREPINEPHRINE REUPTAKE MODULATORS FOR PREVENTING AND TREATING VASOMOTOR SYMPTOMS | WYETH (US) | 2004-04-29 | — | — | WO | claimed |
| US-20090227585-A1 | SUBSTITUTED N-HETEROCYCLE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090227585-A1 | SUBSTITUTED N-HETEROCYCLE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090227585-A1 | SUBSTITUTED N-HETEROCYCLE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
| US-7550456-B2 | Substituted aryl cycloalkanoyl derivatives and methods of their use | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550456-B2 | Substituted aryl cycloalkanoyl derivatives and methods of their use | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-20040152710-A1 | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms | WYETH | 2004-08-05 | — | — | US | disclosed |
| US-20040143008-A1 | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms | WYETH | 2004-07-22 | — | — | US | disclosed |
| WO-2004035036-A1 | A METHOD OF TREATING VASOMOTOR SYMPTOMS COMPRISING A COMPOUND HAVING NOREPINEPHRINE REUPTAKE INHIBITOR ACTIVITY AND 5-HT2A ANTAGONISTIC ACTIVITY | WYETH (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004035035-A1 | USE OF NOREPINEPHRINE REUPTAKE MODULATORS FOR PREVENTING AND TREATING VASOMOTOR SYMPTOMS | WYETH (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004035058-A1 | USE OF NOREPINEPHRINE REUPTAKE MODULATORS FOR PREVENTING AND TREATING VASOMOTOR SYMPTOMS | WYETH (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227585-A1 | SUBSTITUTED N-HETEROCYCLE DERIVATIVES AND METHODS OF THEIR USE | MAOA, MAOB, SDHA | SLC6A2 71/4885SLC6A3 116/4885SLC6A4 44/4885 |
| US-20050143394-A1 | Phenylpiperazine cycloalkanol derivatives and methods of their use | HTR5A, PNMT, HTR3A | SLC6A2 49/4885SLC6A3 100/4885SLC6A4 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.